Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: RMP who wrote (287)	8/5/1998 11:30:00 AM
From: Marc Kahn	Read Replies (1) \| Respond to of 534

There are many subcutaneous and intradermal needle free injector systems on the market, and have been for quite a while. The most successful of these is Mediject (MEDJ). The most common usage for these is for the subcutaneous self-injection of insulin for diabetics. Bioject recently acquired the Vitajet system, which is reputedly the best engineered of the various subcutaneous injectors. The Biojector system is unique in that it can provide intramuscular injections, in addition to subcutaneous and intradermal. Most vaccinations need to be delivered into muscle tissue. There is no competition for Bioject in needle-free intramuscular injections. This is a very strong position, and well protected by patents. Recent discoveries that jet injection of DNA vaccines are much more effectively utilized by the body, as opposed to needle injections, puts Bioject in an even stronger position. Marc Kahn